The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 118, Issue , 2016, Pages 183-192

  Sromova, Lucie ^a   Busek, Petr ^a   Posova, Helena ^a   Potockova, Jana ^a   Skrha, Pavel ^a   Andel, Michal ^a   Sedo, Aleksi ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Diabetes mellitus type 2; Dipeptidyl peptidase 4 inhibition; Gliptins; Immune cells

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADULT; AGED; ARTICLE; CD4 CD8 RATIO; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOLOGIC HOMEOSTASIS; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; MALE; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE COUNT; TREATMENT OUTCOME;

ADULT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; SITAGLIPTIN PHOSPHATE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TREATMENT OUTCOME;

EID: 84977263014     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.06.020     Document Type: Article

References (37)

1. [1] Drucker, D.J., The role of gut hormones in glucose homeostasis. J Clin Investig 117 (2007), 24–32.
2. [2] Havale, S.H., Pal, M., Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 17 (2009), 1783–1802.
3. [3] Tella, S.H., Rendell, M.S., DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf 14 (2015), 127–140.
4. [4] Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., Rajagopalan, S., Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials. J Diabetes Res, 2015, 2015, 606031.
5. [5] Busek, P., Malik, R., Sedo, A., Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 36 (2004), 408–421.
6. [6] Stulc, T., Sedo, A., Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?. Diabetes Res Clin Pract 88 (2010), 125–131.
7. [7] Cui, Y., Andersen, D.K., Diabetes and pancreatic cancer. Endocr Relat Cancer 19 (2012), F9–F26.
8. [8] Cohen, D., Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm. BMJ, 346, 2013, f3900.
9. [9] Gorrell, M.D., Gysbers, V., McCaughan, G.W., CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 54 (2001), 249–264.
10. [10] Yazbeck, R., Howarth, G.S., Abbott, C.A., Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol Sci 30 (2009), 600–607.
11. [11] Wrenger, S., Faust, J., Mrestani-Klaus, C., Fengler, A., Stockel-Maschek, A., Lorey, S., et al. Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. J Biol Chem 275 (2000), 22180–22186.
12. [12] Ohnuma, K., Yamochi, T., Uchiyama, M., Nishibashi, K., Yoshikawa, N., Shimizu, N., et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci U S A 101 (2004), 14186–14191.
13. [13] Balaziova, E., Sedova, L., Mares, V., Vlasicova, K., Sevcik, J., Sedo, A., Dipeptidyl peptidase-IV activity and/or structure homologs (DASH): contributing factors in the pathogenesis of rheumatic diseases?. Adv Exp Med Biol 575 (2006), 169–174.
14. [14] Bergman, A.J., Stevens, C., Zhou, Y., Yi, B., Laethem, M., De Smet, M., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28 (2006), 55–72.
15. [15] Mareckova, H., Ravdan, A., Fucikova, T., Janatkova, I., Detection of the production of intracellular cytokines by T lymphocytes using flow cytometry-methodologic problems. Epidemiol Mikrobiol Imunol 51 (2002), 111–118.
16. [16] Aytac, U., Dang, N.H., CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 4 (2004), 11–18.
17. [17] Wagner, L., Klemann, C., Stephan, M., von Horsten, S., Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homolog (DASH) proteins. Clin Exp Immunol, 2015.
18. [18] Kim, D., Wang, L., Beconi, M., Eiermann, G.J., Fisher, M.H., He, H., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005), 141–151.
19. [19] Price, J.D., Linder, G., Li, W.P., Zimmermann, B., Rother, K.I., Malek, R., et al. Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. Clin Exp Immunol 174 (2013), 120–128.
20. + T cells in patients with type 2 diabetes. Diabetes Res Clin Pract 110 (2015), 250–256.
21. [21] Saito, T., Ohnuma, K., Suzuki, H., Dang, N.H., Hatano, R., Ninomiya, H., et al. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. Diabetes Res Clin Pract 102 (2013), e8–e12.
22. [22] Sasaki, T., Hiki, Y., Nagumo, S., Ikeda, R., Kimura, H., Yamashiro, K., et al. Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. Diabetol Int 1 (2010), 90–92.
23. [23] Yokota, K., Igaki, N., Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. Intern Med 51 (2012), 2041–2044.
24. [24] Baraniuk, J.N., Jamieson, M.J., Rhinorrhea, cough and fatigue in patients taking sitagliptin. Allergy Asthma Clin Immunol, 6, 2010, 8.
25. [25] Aouidad, I., Fite, C., Marinho, E., Deschamps, L., Crickx, B., Descamps, V., A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol 149 (2013), 243–245.
26. [26] Cabrera, S.M., Rigby, M.R., Mirmira, R.G., Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med 12 (2012), 1261–1272.
27. [27] Steinbrecher, A., Reinhold, D., Quigley, L., Gado, A., Tresser, N., Izikson, L., et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 166 (2001), 2041–2048.
28. [28] Fu, S., Zhang, N., Yopp, A.C., Chen, D., Mao, M., Chen, D., et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 – precursors. Am J Transplant 4 (2004), 1614–1627.
29. [29] Preller, V., Gerber, A., Wrenger, S., Togni, M., Marguet, D., Tadje, J., et al. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol 178 (2007), 4632–4640.
30. [30] Tasic, T., Baumer, W., Schmiedl, A., Schwichtenhovel, F., Pabst, R., Raap, U., et al. Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis. Clin Exp Allergy 41 (2011), 1098–1107.
31. [31] Jungraithmayr, W., Oberreiter, B., De Meester, I., Wiedl, T., Inci, I., Bain, M., et al. The effect of organ-specific CD26/DPP IV enzymatic activity inhibitor-preconditioning on acute pulmonary allograft rejection. Transplantation 88 (2009), 478–485.
32. [32] Zhao, Y., Yang, L., Wang, X., Zhou, Z., The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev 30 (2014), 646–653.
33. [33] Boonacker, E., Van Noorden, C.J., The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82 (2003), 53–73.
34. [34] Herlihy, S.E., Brown, M.L., Pilling, D., Weeks, B.R., Myers, L.K., Gomer, R.H., Role of the neutrophil chemorepellent soluble dipeptidyl peptidase IV in decreasing inflammation in a murine model of arthritis. Arthritis Rheumatol 67 (2015), 2634–2638.
35. [35] Sedo, A., Duke-Cohan, J.S., Balaziova, E., Sedova, L.R., Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?. Arthritis Res Ther 7 (2005), 253–269.
36. [36] Sedo, A., Malík, R., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?. Biochim Biophys Acta 1550 (2001), 107–116.
37. [37] Busek, P., Sedo, A., Dipeptidyl peptidase-IV and related proteases in brain tumors. Lichtor, T., (eds.) Evolution of the molecular biology of brain tumors and the therapeutic implications, 2013, InTech.